Alafair Biosciences
Alafair Biosciences is an Austin, Texas–based private medical device company that develops FDA-cleared, bioresorbable hyaluronic-acid and alginate hydrogel devices (VersaWrap Hydrogel Sheet, VersaCoat Flowable Hydrogel) used by orthopedic, spine, and reconstructive surgeons to prevent postoperative soft-tissue tethering and adhesion in tendon, ligament, muscle, and nerve procedures.
- Company typePrivate
- Founded2016
- HeadquartersAustin, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alafair Biosciences does
Alafair Biosciences, Inc. is a privately held medical device company headquartered in Austin, Texas, that develops, manufactures, and commercializes bioresorbable soft-tissue protection devices built on its proprietary VersaCore Hydrogel Technology platform. The platform combines naturally derived high-molecular-weight hyaluronic acid and alginate into a collagen-free, dye-free, selectively permeable hydrogel that provides a protective gliding surface between adjacent tissue planes to prevent postoperative tethering and scar-tissue adherence. The commercial portfolio consists of VersaWrap Hydrogel Sheet (an ultrathin, sutureless, conformable sheet FDA-cleared in 2016 for tendon and in 2020 for peripheral nerve), the VersaWrap Application Kit (which converts a sheet into syringe-deliverable gel), and VersaCoat Flowable Hydrogel (a ready-to-use syringe-deliverable gel FDA-cleared in July 2025 and commercially launched in June 2026). The technology is protected by 23 granted US patents.
The company serves US-based orthopedic, upper-extremity, spine, and plastic and reconstructive surgeons performing tendon repair, ligament repair, skeletal muscle protection, and peripheral nerve procedures across hospitals, surgical centers, and physician offices. As of June 2026, VersaWrap Hydrogel Sheet had been implanted in more than 40,000 patients. The business model is one-time hardware sales per surgical case, distributed through a direct field sales organization with a dedicated field reimbursement team (supporting prior authorizations and appeals) and an independent distributor network managed via a distributor portal. Pricing is quote-based and not publicly disclosed. The company holds GPO agreements with Premier, Inc. (2024) and an Innovative Technology Contract with Vizient (2025), and is generating indication-expanding evidence through multi-center clinical studies including the B.R.A.A.D study for Achilles tendon repair (enrollment initiated June 2025 at UC Davis).
Alafair has achieved 722% three-year revenue growth and has appeared on the Inc. 5000 list for three consecutive years (No. 574 in 2025, up 254 spots). It is led by co-founder John Joyoprayitno (President & CEO) alongside co-founders Sarah Mayes PhD (CSO) and Dan Peterson MD, with a commercial-heavy C-suite drawn from Zimmer Biologics, Medtronic, NuVasive, Stryker (via Orthovita), and Novartis. The company has been recognized on Inc.'s Best Workplaces lists (2025 and 2026) and the co-founding team was named a finalist for the EY Entrepreneur Of The Year 2026 Gulf South Award.
Alafair Biosciences firmographics
Firmographics- Name
- Alafair Biosciences
- Legal name
- Alafair Biosciences, Inc.
- Website
- https://alafairbiosciences.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Alafair Biosciences is an Austin, Texas–based private medical device company that develops FDA-cleared, bioresorbable hyaluronic-acid and alginate hydrogel devices (VersaWrap Hydrogel Sheet, VersaCoat Flowable Hydrogel) used by orthopedic, spine, and reconstructive surgeons to prevent postoperative soft-tissue tethering and adhesion in tendon, ligament, muscle, and nerve procedures.
- Ownership category
- akta.pro rank
Alafair Biosciences industry classification
Industry- Product category
- Soft-Tissue Protection Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair) (HLAHAEAF)
- akta.pro secondary industries
- Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where Alafair Biosciences is headquartered
LocationHeadquarters
- HQ city
- Austin
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Alafair Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
Revenue model
- Medical Device Sales: Alafair generates revenue through the sale of its FDA-cleared medical devices including VersaWrap Hydrogel Sheet and VersaCoat Flowable Hydrogel. Products are sold directly to healthcare facilities and through distributor networks as one-time surgical products with no recurring revenue from customers.
- Reimbursement Support Services: The company provides field reimbursement support services including prior authorization assistance and appeals support for patients, which complements product sales to healthcare facilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing for VersaWrap and VersaCoat products |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels6 records
Alafair Biosciences product offering
Product offeringCore offering
Alafair Biosciences develops and commercializes FDA-cleared, bioresorbable hydrogel medical devices for protecting tendon, ligament, skeletal muscle, and peripheral nerve tissues during surgical repair. Its current portfolio includes VersaWrap Hydrogel Sheet, VersaCoat Flowable Hydrogel, and the VersaWrap Application Kit, all based on the proprietary VersaCore platform for maintaining a protective gliding surface and reducing postoperative tethering.
Product overview
Alafair Biosciences offers a portfolio of FDA-cleared bioresorbable medical devices built on the proprietary VersaCore Hydrogel Technology platform. The portfolio consists of VersaWrap Hydrogel Sheet (a conformable, sutureless sheet that can also be converted to gel format using the VersaWrap Application Kit) and VersaCoat Flowable Hydrogel (a ready-to-use syringe-deliverable gel). Both products are based on naturally-derived hyaluronic acid and alginate, providing protective gliding surfaces to prevent postoperative tethering during tendon, ligament, muscle, and nerve repair procedures.
Differentiator
Problem solved
Functional benefit
Brands
- VersaCore: Proprietary naturally-derived biopolymer platform technology behind the company's soft-tissue protection portfolio, combining hyaluronic acid and alginate
- VersaWrap
- VersaCoat
Products and services
- VersaCoat™ Flowable Hydrogel A syringe-deliverable, bioresorbable soft-tissue protection device that forms a tissue-adherent gel layer and sustained gliding surface to reduce postoperative tethering. It is cleared for tendon, ligament, skeletal muscle, and peripheral nerve applications and is available in 1 mL and 2 mL volumes.
- VersaWrap® Hydrogel Sheet A conformable, sutureless, non-swelling, bioresorbable hydrogel sheet that provides a sustained gliding surface between opposing tissues to reduce friction and postoperative tethering. It is cleared for tendon, ligament, skeletal muscle, and peripheral nerve applications and is available in 1x2 inch and 2x2 inch sizes.
- VersaWrap® Application Kit An accessory kit that converts a 5x5 cm VersaWrap Hydrogel Sheet into 0.5 mL of syringe-deliverable gel for targeted application in complex or difficult-to-access anatomical sites. The kit includes syringes, a connector, and wetting solution.
Quantifiable outcome
- 40,000+ implants with VersaWrap Hydrogel Sheet demonstrating clinical adoption and safety profile
- +3 more outcomes
Companies that use Alafair Biosciences
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Alafair Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Alafair Biosciences partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Premier, Inc.coreAlafair Biosciences was awarded a Synthetic Implantable Products Agreement with Premier, Inc. for VersaWrap Hydrogel Sheet. This GPO agreement provides access to Alafair's products through Premier's network of healthcare facilities.
- VizientcoreAlafair Biosciences received an Innovative Technology Contract from Vizient for VersaWrap. The company exhibited at the Vizient Innovative Technology Exchange, positioning VersaWrap as an innovative technology for Vizient member hospitals.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Alafair Biosciences competitors and assessment
Company assessmentDirect peers
- Anika Therapeutics: Anika develops hyaluronic acid-based medical products for orthopedic, sports medicine, and wound healing applications. Alafair's hyaluronic acid/alginate VersaCore hydrogel addresses the same anti-adhesion and soft-tissue protection use cases Anika targets with its viscosupplementation and regenerative franchises.
Broad incumbents
- Arthrex: Arthrex is the dominant privately held sports medicine and orthopedic soft-tissue repair company, selling anchors, grafts, and biologic adjuncts. While Arthrex does not sell a direct hydrogel anti-adhesion equivalent, it controls the surgeon relationships and procedural channels where VersaWrap and VersaCoat are adopted.
- Smith+Nephew: Smith+Nephew's Sports Medicine franchise sells tendon repair implants, anchors, and regenerative scaffolds in the same procedures where Alafair's hydrogel sheet is used. As a broad incumbent it can bundle or compete against VersaWrap/VersaCoat in hospital contracts.
- Stryker: Stryker (including its Orthovita sports medicine heritage, where Alafair's CMO previously worked) offers orthopedic biologics and soft-tissue repair products. As a large incumbent, Stryker has the surgeon access and capital to compete in the anti-adhesion space.
- Integra LifeSciences: Integra manufactures regenerative wound dressings, skin substitutes, and surgical implants for soft-tissue repair. Its regenerative wound healing and dural repair products overlap with Alafair's soft-tissue protection use cases in surgical settings.
- Conmed: Conmed's orthopedic/sports medicine portfolio includes tissue repair devices, anchors, and surgical consumables used in the same tendon and ligament procedures where VersaWrap is adopted. It competes for hospital budget allocation and surgeon loyalty.
Emerging players
- MiMedx: MiMedx markets placental tissue allografts for wound healing, soft-tissue recovery, and surgical applications. It targets adjacent regenerative and tissue protection use cases to Alafair's VersaCore platform.
- Organogenesis: Organogenesis develops regenerative skin and soft-tissue products including advanced wound care dressings and surgical biologics. It competes in adjacent regenerative surgery markets where anti-adhesion and soft-tissue protection are relevant.
- Isto Biologics: Isto Biologics develops orthobiologic products for spine, sports medicine, and orthopedic surgery, including bone graft substitutes and soft-tissue repair scaffolds. It overlaps with Alafair's tendon, ligament, and surgical soft-tissue applications.
- Bioventus: Bioventus offers orthobiologic solutions for pain management, joint preservation, and surgical recovery. Its surgical recovery and regenerative products compete in adjacent orthopedic soft-tissue healing indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Alafair Biosciences social profiles
Digital presenceAlafair Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alafair Biosciences leadership team
Management profileNumber of profiles
Profiles7 records
Alafair Biosciences funding detail
Funding detailFunding overview
Funding rounds7 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alafair Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alafair Biosciences
What does Alafair Biosciences do?
Alafair Biosciences develops and commercializes FDA-cleared, bioresorbable hydrogel medical devices for protecting tendon, ligament, skeletal muscle, and peripheral nerve tissues during surgical repair. Its current portfolio includes VersaWrap Hydrogel Sheet, VersaCoat Flowable Hydrogel, and the VersaWrap Application Kit, all based on the proprietary VersaCore platform for maintaining a protective gliding surface and reducing postoperative tethering.
Is Alafair Biosciences a public or private company?
Alafair Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alafair Biosciences founded?
Alafair Biosciences was founded in 2016. It employs 11 to 50 people.
Where is Alafair Biosciences based?
Alafair Biosciences is headquartered in Austin, United States, in the North America region.
How does Alafair Biosciences make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are reimbursement Support Services.
Who are Alafair Biosciences's main competitors?
Anika Therapeutics is listed as a direct peer. Broad incumbents are Arthrex, Smith+Nephew, Stryker, Integra LifeSciences and Conmed. Emerging players are MiMedx, Organogenesis, Isto Biologics and Bioventus.
Does Alafair Biosciences have an API?
No public API is recorded for Alafair Biosciences.
What industry is Alafair Biosciences in?
Alafair Biosciences's product category is Soft-Tissue Protection Medical Devices. Its primary akta.pro industry code is HLAHAEAF, Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair), with a secondary code of HLAHAEAB, Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation). Its NAICS code is 339113 and its SIC code is 3842.